Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Aducanumab→

Aducanumab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1384260-65-4
Molecular formula
C6472H10028N1740O2014S46
Molecular weight
145910.4 g/mol
Drug class
Anti-amyloid beta (Aβ) human monoclonal IgG1 antibodyhistorical Alzheimer disease disease-modifying biologic
Mechanism of action
Binds aggregated soluble and insoluble amyloid beta, including oligomers and fibrils, promoting reduction of amyloid plaque burden. This is the pharmacological rationale; clinical benefit was not established to the level required for continued approval.
Indications / reported uses
  • Historical US indication: treatment of Alzheimer disease initiated in patients with mild cognitive impairment or mild dementia stage, following confirmation of amyloid pathology. Aduhelm was withdrawn from clinical use and its US approval was withdrawn on 1 November 2024; it is not a current treatment option.

Sources: NCBI Bookshelf — Aducanumab (Aduhelm) status and withdrawal · FDA — Aduhelm prescribing information (historical label) · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Anti-amyloid beta (Aβ) human monoclonal IgG1 antibody; historical Alzheimer disease disease-modifying biologic

Mechanism of action

Binds aggregated soluble and insoluble amyloid beta, including oligomers and fibrils, promoting reduction of amyloid plaque burden. This is the pharmacological rationale; clinical benefit was not established to the level required for continued approval.

General use cases

  • Historical US indication: treatment of Alzheimer disease initiated in patients with mild cognitive impairment or mild dementia stage, following confirmation of amyloid pathology. Aduhelm was withdrawn from clinical use and its US approval was withdrawn on 1 November 2024; it is not a current treatment option.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Aducanumab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Aducanumab Permitted Daily Exposure (PDE) report (the Aducanumab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Aducanumab Occupational Exposure Limit (OEL) report (the Aducanumab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.